Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.3.1339

Mitochondrial DNA Levels in Blood and Tissue Samples from Breast Cancer Patients of Different Stages  

Xia, Peng (Department of Oncology Surgery, First Affiliated Hospital, Xi'an Jiaotong University)
Wang, Hui-Juan (School of Life Sciences, Northwest University)
Geng, Ting-Ting (School of Life Sciences, Northwest University)
Xun, Xiao-Jie (School of Life Sciences, Northwest University)
Zhou, Wen-Jing (School of Life Sciences, Northwest University)
Jin, Tian-Bo (School of Life Sciences, Northwest University)
Chen, Chao (School of Life Sciences, Northwest University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.3, 2014 , pp. 1339-1344 More about this Journal
Abstract
Aims: Alterations in mitochondrial DNA (mtDNA) have been implicated in carcinogenesis and tumor progression. We here evaluated the diagnostic and prognostic potential of mtDNA as a biomarker for breast cancer. Methods: Using multiplex real-time polymerase chain reaction, nuclear DNA (nDNA) and mtDNA levels in serum, buffy coat, tumor, and tumor-adjacent tissue samples from 50 breast cancer patients were determined and assessed for associations with clinicopathological features. To evaluate mtDNA as a biomarker for distinguishing between the four sample types, we created receiver operating characteristic (ROC) curves. Results: The mtDNA levels in buffy coat were significantly lower than in other sample types. Relative to tumor-adjacent tissue, reduced levels of mtDNA were identified in buffy coat and tumor tissue but not in serum. According to ROC curve analysis, mtDNA levels could be used to distinguish between buffy coat and tumor-adjacent tissue samples with good sensitivity (77%) and specificity (83%). Moreover, mtDNA levels in serum and tumor tissue were positively associated with cancer TMN stage. Conclusions: The mtDNA levels in blood samples may represent a promising, non-invasive biomarker in breast cancer patients. Additional, large-scale validation studies are required to establish the potential use of mtDNA levels in the early diagnosis and monitoring of breast cancer.
Keywords
Mitochondrial DNA (mtDNA); quantitative alterations; blood; tissue; breast cancer;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Zhu W, Qin W, Sauter ER (2004). Large-scale mitochondrial DNA deletion mutations and nuclear genome instability in human breast cancer. Cancer Detect Prev, 28, 119-26.   DOI   ScienceOn
2 Wu CW, Yin PH, Hung WY, et al (2005). Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer, 44, 19-28.   DOI   ScienceOn
3 Wang Y, Liu VW, Xue WC, Cheung AN, Ngan HY (2006). Association of decreased mitochondrial DNA content with ovarian cancer progression. Br J Cancer, 95, 1087-91.   DOI   ScienceOn
4 Wang Y, Liu VW, Xue WC, et al (2005). The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: a quantitative study using laser-captured microdissected tissues. Gynecol Oncol, 98, 104-10.   DOI   ScienceOn
5 Weigel MT, Dowsett M (2010). Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer, 17, R245-62.   DOI   ScienceOn
6 Xia P, An HX, Dang CX, et al (2009a). Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. BMC Cancer, 9, 454.   DOI   ScienceOn
7 Xia P, Radpour R, Zachariah R, et al (2009b). Simultaneous quantitative assessment of circulating cell-free mitochondrial and nuclear DNA by multiplex real-time PCR. Genet Mol Biol, 32, 20-4.   DOI   ScienceOn
8 Xing J, Chen M, Wood CG, et al (2008). Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst, 100, 1104-12.   DOI   ScienceOn
9 Yin PH, Lee HC, Chau GY, et al (2004). Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma. Br J Cancer, 90, 2390- 6.
10 Yu M (2011). Generation, function and diagnostic value of mitochondrial DNA copy number alterations in human cancers. Life Sci, 89, 65-71.   DOI   ScienceOn
11 Yu M, Zhou Y, Shi Y, et al (2007). Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life, 59, 450-7.   DOI   ScienceOn
12 Okochi O, Hibi K, Uemura T, et al (2002). Detection of mitochondrial DNA alterations in the serum of hepatocellular carcinoma patients. Clin Cancer Res, 8, 2875-8.
13 Mizumachi T, Muskhelishvili L, Naito A, et al (2008). Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells. Prostate, 68, 408-17.   DOI   ScienceOn
14 Morten KJ, Ashley N, Wijburg F, et al (2007). Liver mtDNA content increases during development: a comparison of methods and the importance of age- and tissue-specific controls for the diagnosis of mtDNA depletion. Mitochondrion, 7, 386-95.   DOI   ScienceOn
15 Nomoto S, Yamashita K, Koshikawa K, Nakao A, Sidransky D (2002). Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res, 8, 481-7.
16 Tseng LM, Yin PH, Chi CW, et al (2006). Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer, 45, 629-38.   DOI   ScienceOn
17 Radpour R, Fan AX, Kohler C, Holzgreve W, Zhong XY (2009). Current understanding of mitochondrial DNA in breast cancer. Breast J, 15, 505-9.   DOI   ScienceOn
18 Selvanayagam P, Rajaraman S (1996). Detection of mitochondrial genome depletion by a novel cDNA in renal cell carcinoma. Lab Invest, 74, 592-9.
19 Thyagarajan B, Wang R, Nelson H, et al (2013). Mitochondrial DNA copy number is associated with breast cancer risk. PLoS One, 8, e65968.   DOI   ScienceOn
20 Wang K, Yuan Y, Cho JH, et al (2012). Comparing the MicroRNA spectrum between serum and plasma. PLoS One, 7, e41561.   DOI
21 Jiang WW, Rosenbaum E, Mambo E, et al (2006). Decreased mitochondrial DNA content in posttreatment salivary rinses from head and neck cancer patients. Clin Cancer Res, 12, 1564-9.   DOI   ScienceOn
22 Hibi K, Nakayama H, Yamazaki T, et al (2001). Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients. Int J Cancer, 94, 429-31.   DOI   ScienceOn
23 Jiang WW, Masayesva B, Zahurak M, et al (2005). Increased mitochondrial DNA content in saliva associated with head and neck cancer. Clin Cancer Res, 11, 2486-91.   DOI   ScienceOn
24 Jones JB, Song JJ, Hempen PM, et al (2001). Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res, 61, 1299-304.
25 Mehra N, Penning M, Maas J, et al (2007). Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res, 13, 421-6.   DOI   ScienceOn
26 Kohler C, Radpour R, Barekati Z, et al (2009). Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer, 8, 105.   DOI   ScienceOn
27 Lee HC, Li SH, Lin JC, et al (2004). Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res, 547, 71-8.   DOI   ScienceOn
28 Mambo E, Chatterjee A, Xing M, et al (2005). Tumor-specific changes in mtDNA content in human cancer. Int J Cancer, 116, 920-4.   DOI   ScienceOn
29 Barrientos A, Casademont J, Cardellach F, et al (1997). Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Brain Res Mol Brain Res, 52, 284-9.   DOI   ScienceOn
30 Bewick V, Cheek L, Ball J (2004). Statistics review 10: further nonparametric methods. Crit Care, 8, 196-9.   DOI   ScienceOn
31 Copeland WC, Wachsman JT, Johnson FM, Penta JS (2002). Mitochondrial DNA alterations in cancer. Cancer Invest, 20, 557-69.   DOI   ScienceOn
32 Dai JG, Zhang ZY, Liu QX, Min JX (2013). Mitochondrial genome microsatellite instability and copy number alteration in lung carcinomas. Asian Pac J Cancer Prev, 14, 2393-9.   과학기술학회마을   DOI   ScienceOn
33 Dani MA, Dani SU, Lima SP, et al (2004). Less DeltamtDNA4977 than normal in various types of tumors suggests that cancer cells are essentially free of this mutation. Genet Mol Res, 3, 395-409.
34 Jeronimo C, Nomoto S, Caballero OL, et al (2001). Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene, 20, 5195-8.   DOI   ScienceOn
35 Fan AX, Radpour R, Haghighi MM, et al (2009). Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer. J Cancer Res Clin Oncol, 135, 983-9.   DOI
36 Fliss MS, Usadel H, Caballero OL, et al (2000). Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science, 287, 2017-9.   DOI   ScienceOn
37 Gonzalez-Masia JA, Garcia-Olmo D, Garcia-Olmo DC (2013). Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther, 6, 819-32.
38 Shen J, Platek M, Mahasneh A, Ambrosone CB, Zhao H (2010). Mitochondrial copy number and risk of breast cancer: a pilot study. Mitochondrion, 10, 62-8.   DOI   ScienceOn